The utility of STING agonist (STINGa), namely cGAMP and other cyclic dinucleotides (CDNs), in the treatment of cancer is in early phase of clinical testing (7), and ongoing efforts are directed toward overcoming its unfavorable pharmacological profile and poor bioavailability (9, 10, 11, 12). Here, STING1 is linked to cancer.